Ranibizumab for the treatment of macular edema following retinal vein occlusion
نویسندگان
چکیده
Retinal vein occlusions (RVOs) are the second most common form of retinal vascular disease. The Beaver Dam Study estimated the 15 year cumulative incidence of RVOs at 2.3%. The predominant causes for vision loss from RVOs include macular edema and macular ischemia. Data from historic studies recommended focal macular laser only for branch vein occlusion patients with macular edema and >20/40 vision within 3–18 months of onset and without significant retinal hemorrhages. No treatment for macular edema was recommended for central vein occlusion patients. For years, the standard of care has been extrapolated from these historic studies. However, exciting new data from two multicenter randomized controlled studies using ranibizumab for the treatment of macular edema in vein occlusions have yielded impressive results, reshaping the management of RVO.
منابع مشابه
Outcomes of Intravitreal bevacizumab in patients with acute branch retinal vein occlusion
Introduction: The study aimed to evaluate the long-term effects of intravitreal bevacizumab on macular edema and visual acuity in patients with Acute branch Retinal Vein Occlusion (BRVO) that had not received any treatment. Methods: 22 patients in first week of BRVO onset that was diagnosed with flurcein angiography were treated with intravitreal injection of 1.25 mg bevacizumab. Macular thicke...
متن کاملSafety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for ...
متن کاملRanibizumab for macular edema secondary 1 to retinal vein occlusion : a meta - analysis of 2 dose effects and comparison with no 3 anti - VEGF treatment
متن کامل
Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion
Background: Retinal vein occlusions are one of the most common form of retinal vascular disorders and could lead to vision loss due to macular edema, macular ischemia and sequelae from neovascularization. Anti-venous endothelial growth factor (anti-VEGF) treatment is the choice strategy of treatment for patients with macular edema secondary to central retinal vein occlusion (CRVO). There is an ...
متن کاملRole of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials
For years, the standard of care for branch-retinal-vein-occlusion-associated macular edema was initial observation followed by grid-pattern laser photocoagulation for persistent edema. Newer pharmacologic options have revolutionized the management of branch-retinal-vein-occlusion-associated macular edema, and the visual outcomes of these eyes are better than ever. However, a variety of availabl...
متن کامل